Literature DB >> 21740101

Designing modulators of dimethylarginine dimethylaminohydrolase (DDAH): a focus on selectivity over arginase.

Juerke Kotthaus1, Dennis Schade, Joscha Kotthaus, Bernd Clement.   

Abstract

DDAH inhibition presents a novel promising pharmaceutical strategy to lower NO formation. To date, several potent DDAH inhibitors have been published, most of them representing analogues of l-arginine. While inhibitory effects on NOSs have already been considered, selectivity over arginase has been neglected so far. In our view, the latter selectivity is more important since an additional inhibition of arginase decreases the desired effects on NO levels. Thus, we particularly focus on selectivity over arginase. We present a comprehensive selectivity profile of known DDAH inhibitors by covering their inhibitory potency on arginase. Among the studied compounds, N(ω)-(2-methoxyethyl)-l-arginine (2a, L-257) that is already selective over NOSs also only modestly affected arginase activity and is thus far the most suitable DDAH inhibitor for pharmacological studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21740101     DOI: 10.3109/14756366.2011.573480

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  2 in total

1.  Developing an irreversible inhibitor of human DDAH-1, an enzyme upregulated in melanoma.

Authors:  Yun Wang; Shougang Hu; Abdul M Gabisi; Joyce A V Er; Arthur Pope; Gayle Burstein; Christopher L Schardon; Arturo J Cardounel; Suhendan Ekmekcioglu; Walter Fast
Journal:  ChemMedChem       Date:  2014-02-26       Impact factor: 3.466

2.  Discovery of structurally-diverse inhibitor scaffolds by high-throughput screening of a fragment library with dimethylarginine dimethylaminohydrolase.

Authors:  Thomas W Linsky; Walter Fast
Journal:  Bioorg Med Chem       Date:  2012-08-03       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.